Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


04. September 2020 | 09:48 CET

Moderna, Evotec or Valeo Pharma: Who has the game changer?

  • Covid-19
Photo credits: pixabay.com

The pandemic is driving the markets. But sometimes investors either come too late or bet on the wrong horse. In the analysis, three stocks for which investors hope for the game changer. The fact that the search for a cure for Covid-19 is making high waves on the stock market is shown by stocks like Moderna. Despite the current price correction, the biotech company from the USA achieves an annual performance of a massive 280%. The reason for this soaring performance is easy to find: Moderna is researching a Corona vaccine and has already reported promising interim results. Among other things, the EU has already secured several million vaccine doses in the event of a successful clinical approval procedure.

time to read: 2 minutes by Nico Popp


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


Established biotech players between hype and passivity

However, with a market capitalization of more than EUR 21 billion, the market has already given a lot of advance praise. It is considered certain that the one vaccine against Corona will not be available, but Moderna shareholders must ask themselves whether the level in the share price has not become too high given the hype of recent months. Whereas BioNTech was previously considered Moderna's main competitor, AstraZeneca has now also caught up with a similar approach and is in a test series with 30,000 volunteers in the USA.

Evotec's shares are significantly more conservative than Moderna's. The Hamburg-based company is focused on the research and development of new active ingredients and cooperates with Bayer, Genentech, Roche and AstraZeneca, among others. At the end of July, Evotec announced that a subsidiary in the USA will cooperate with the US Department of Defense in the search for measures against Covid-19.

On the stock market, this news left most investors unimpressed: While Moderna had a one-year run, Evotec's share price has only increased moderately by 16%. Why is this? Unlike pure Covid-19 plays, Evotec is about research into drugs for all diseases. These include diabetes, cancer and cardiovascular diseases. Evotec is valued at EUR 3.4 billion on the stock market - despite the pandemic, the share price has not changed that much so far.

Approval for Hesperco™ - Product before sales start

A completely different share is the Canadian company Valeo Pharma. The manufacturer of special pharmaceuticals is currently valued at only about 43 million EUR and is thus a very small company compared to Moderna or Evotec. But for this very reason investors should take a close look at the possible perspective of an investment. Valeo Pharma distributes Hesperco™, an antioxidant that is supposed to support the immune system.

In the opinion of Pierre Laurin, President and CEO of Ingenew, a research company with which Valeo Pharma collaborates, the active ingredient is suitable for fighting the consequences of symptoms associated with Corona viruses. Yesterday, the Canadian Ministry of Health Canada granted Valeo Pharma the natural product license, authorizing the sale of Hesperco™. As the company also announced, sales are scheduled to begin as early as the end of September 2020.

Speculative investors should think outside the box

While the use of antioxidants in the context of serious diseases can only be a supporting measure and should be discussed with treating physicians, investors should not ignore Valeo Pharma's recent success. In view of the current threat, the proven positive effect of Hesperco™ on the immune system could result in sales opportunities for Valeo Pharma.

While new medical products or research projects are less important for companies such as Evotec in terms of share price, a success of Hesperco™ could be a game changer for Valeo Pharma. At a time when many of the well-known "vaccine stocks" are already ambitiously valued and also highly volatile, it may be a good time for speculative investors to think outside the box.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. February 2021 | 08:15 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Johnson & Johnson: biotech gems from the well-known to the unknown

  • Covid-19

If there's one industry that's rightfully making big profits these days, it's healthcare companies. The pandemic has kissed the industry awake. In addition to the current relevance around Covid treatment, test procedures, or even vaccinations, there is also a growing awareness that medical innovation depends on research. More and more investors are willing to push promising projects and the general conditions for this could not be better. There is a consensus in politics, society and business that health is the highest good.

Read

21. December 2020 | 07:50 CET | by Stefan Feulner

CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!

  • Covid-19

The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.

Read

02. November 2020 | 09:07 CET | by Stefan Feulner

Ballard Power, Saturn Oil & Gas, Amazon - The profiteers of the crisis!

  • Covid-19

The profiteers of the first wave of the Corona pandemic are seen from the most recently published quarterly figures. The well-known FAANG stocks Facebook, Amazon, Apple, Netflix and Alphabet (Google) were able to improve their balance sheets significantly. Besides some winners, the number of losers is much larger. These now either have to fight for survival or are swallowed cheaply by financially more robust competitors. The takeover wave should pick up speed in 2021, across all industries!

Read